(Reuters) - German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.
"We are serving all key players in the GLP-1 market," he said during an earnings call. "There are only two key players there."
The current sales result is thanks to deliveries to these customers, he added.
GLP-1 is a type of obesity drug such as Novo Nordisk (CSE:NOVOb)'s Wegovy and Eli Lilly (NYSE:LLY)'s Zepbound, which is administered by injector pens such as those made by Gerresheimer.